Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Company Details
Coave Therapeutics Questions
Coave Therapeutics's website is horama.fr
Coave Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/coavetx
Coave Therapeutics has
45 employees.
View email and phone details for 45
employees at Coave Therapeutics.
Coave Therapeutics's industry is
Biotechnology Research
Coave Therapeutics's top competitors are
Corteria Pharmaceuticals,
Abivax,
Enterome,
Sparingvision,
Treefrog Therapeutics,
Cellectis,
Mnemo Therapeutics,
Imcheck Therapeutics,
Nanobiotix,
Innate Pharma.
Coave Therapeutics's categories are Biotechnology Research
Coave Therapeutics's founding year is 2014
